Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
Advaxis
Immunotherapy Trains the Immune System to Attack Cancer Cells
Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
Advaxis Receives Best Therapeutic Vaccine Award
The 5th Annual Vaccine Industry Excellence Awards has named Advaxis as the Best Therapeutic Vaccine for the company’s ADVX-HPV construct.
Advaxis Nominated for Vaccine Industry Excellence Award
The company has been selected for the shortlist of the 5th Annual Vaccine Industry Excellence (ViE) Awards in the category of Best Therapeutic Vaccine.
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Advaxis CEO Tom Moore Discovers A New Way To Fight Cancer
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.
Hospital Acquired Infections Becomes A Leading Cause In Patient Deaths
Hospital Acquired Infections, also known as Healthcare-associated infections are the 4th leading cause of patient deaths, killing 270 people per day in the USA.
For Advaxis, Bacteria Help More Than They Hurt
The idea of using harmful bacteria to treat disease might strike many as an odd concept.
Advaxis at the 2010 OneMedForum
Thomas A. Moore, CEO of Advaxis, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.